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of neuronal activity
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Available online at www.sciencedirect.comToward the functional dissection of neuronal circuits, a number
of new genetic tools have been developed that enable rapid
and reversible manipulation of genetically defined neuronal
subtypes in intact mammalian brain circuits. Alongside the
breakthrough technology of optogenetics, receptor–ligand
pairs provide complementary approaches to modulate
neuronal activity using chemical genetics.
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Introduction
In neuroscience, electrical stimulation, lesions, and inac-
tivation of brain areas have allowed functional mapping of
discrete regions and nuclei [1–5]. However, to understand
how these regions produce meaningful output, analysis
has to zoom into the level of individual cell-types that
constitute local circuits. To this end, clever transgenic
methods employing cell type-specific promoters have
been used for neuronal ablation [6,7], inactivation [8–
11], or inhibition of transmitter release [12–15]. Although
some of these methods permit regulation on a timescale
of days to weeks, they are in principle chronic and
preclude precise temporal deconstruction of complex
biological processes. In addition, chronic interventions
are susceptible to compensatory interference [16]. Along-
side the exquisite temporal resolution afforded through
optogenetics [17–19], complementary chemical-genetic
approaches that permit rapid and reversible manipulation
Open access under CC BY license.Current Opinion in Neurobiology 2012, 22:54–60 of neuronal function have now advanced from a proof of
principle stage to physiological application.
Here, we review recent developments in chemical-
genetic tools for manipulating neuronal activity via
receptor–ligand pairs and discuss their application in
mammalian brain circuits.
Manipulating neuronal activity with ionotropic
receptors
The most direct way to pharmacologically regulate the
activity of neuronal cell-types is through targeted expres-
sion of ligand-gated ion channels (LGICs), followed by
activation with exogenous ligands (Figure 1a). An example
is the transgenic overexpression of high affinity acetyl-
choline receptors (nAChRs) in dopaminergic neurons,
which resulted in hyperdopaminergic behavior upon
low-dose administration of nicotine [20]. However, to allow
versatile and precise manipulations of neuronal activity,
receptor–ligand pairs must be orthogonal. That is, neither
the receptor nor its ligand must have endogenous inter-
action partners. In addition, the receptor must not show
activity in the absence of the ligand, which in turn must not
be toxic. Common approaches have been to either hijack
receptor–ligand pairs from other tissues and species, or to
re-engineer endogenous ionotropic receptors.
Neuronal activation with transient receptor
potential channels
One of the first successful methods to drive neuronal firing
using targeted expression of ionotropic receptors was
afforded through the identification of the transient receptor
potential cation channel subfamily V member 1 (TRPV1),
which is mainly expressed in nociceptive peripheral
neurons [21]. When expressed in primary neuronal cul-
tures, TRPV1 drives strong inward currents and membrane
depolarization in the presence of vanilloid-like ligands,
including the pungent molecule capsaicin [21–23]. Sim-
ilarly, TRPM8 transduces electrochemical signals in the
presence of menthol [22,24]. Although effective for ligand-
dependent membrane depolarization, use of TRPV1 for
circuit analysis is complicated by baseline effects in the
absence of ligand gating, and excitotoxicity in the presence
of high agonist concentrations [22,25]. Nevertheless, in
mice conditionally expressing TRPV1, moderate doses of
capsaicin have been shown to reversibly induce dose-de-
pendent neuronal firing on a timescale of seconds without
overt agonist-independent baseline effects or excitotoxi-
city [26]. Furthermore, unilateral activation of striatal
neurons in these mice resulted in contra-lateral turningwww.sciencedirect.com
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Receptor–ligand systems for rapid modulation of neuronal activity. (a) Left, Ligand-gated influx of free Na+ activates voltage-gated calcium channels
(VGCC), resulting in Ca2+ influx, depolarization, and increased firing. Middle, ligand-gated influx of Cl results in hyperpolarization and neuronal
inhibition. Right, Pharmacologically selective effector molecule (PSEM)-gated influx of cations, calcium, or chloride through combination of
pharmacologically selective actuator modules (PSAMs) with different ion-pore domains to manipulate neuronal activity or inhibition, respectively. (b)
Second messenger cascades associated with Gq, and Gi signaling. Left, Gq signaling activates Phospholipase C beta (PLC-b), which hydrolyzes
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). This leads to increased levels of free Ca
2+ or
protein kinase C (PKC) activation. Reductions in PIP2 levels may also lead to closure of KCNQ channels causing depolarization and increased neuronal
firing. Right, Gi signaling activates inward rectifying potassium channels (GIRKs), resulting in hyperpolarization and inhibition. Independently, activated
Gi also inhibits adenylyl cyclase (AC), which promotes cAMP formation and protein kinase A (PKA) activation.behavior starting within 5 min of capsaicin application and
lasting for about 10 min [26]. ‘Caging’ ligands for light
controllable photo release [22] further enhances the
temporal and spatial resolution of this technology. A dis-
advantage of the TRPV1 approach is that capsaicin acti-
vates peripheral pain receptors and does not readily cross
the BBB. In vivo experiments will thus benefit from
TRPV1 null backgrounds, and the use of other vanil-
loid-like molecules with better binding kinetics, and
BBB permeability to allow systemic ligand administration.
Neuronal silencing with ivermectin-gated
chloride channels
For many experimental applications that probe circuit
function in vivo, inhibition rather than excitation of
neuronal populations is desired. Toward this goal, Lechner
et al. have taken advantage of a glutamate-gated chloride
channel (GluCl) from Caenorhabditis elegans, which is acti-
vated by the anthelmintic drug ivermectin [27–29]. Mam-
malian neurons expressing the GluCl a and b subunits in
vitro showed ivermectin-induced membrane potential
hyperpolarization and action potential shunting withinwww.sciencedirect.com seconds, but delayed ligand unbinding and recovery
[27]. In vivo intraperitoneal injection of ivermectin evoked
turning behavior in mice with unilateral striatal GluCl
expression, which peaked 12–48 hours after injection
and lasted for days [29]. This silencing method has since
been used in mice to investigate the roles of subtypes of
GABAergic amygdala neurons in fear conditioning and
hypothalamic neurons in aggression [30,31]. Challenges
associated with variability in receptor expression, and the
need for two subunits [29–31] might be overcome by
implementing human a1 glycine receptor subunits engin-
eered to have low glycine, but high ivermectin sensitivity
[32]. For this system, however, potential interference with
endogenous glycinergic transmission still has to be tested.
Chemically and genetically engineered ligand-
gated ion channels
Magnus et al. have mutated the ligand-binding domain of
the a7 nicotinic acetylcholine receptor to be un-respon-
sive to the endogenous ligand acetylcholine, but highly
sensitive to a variety of small molecule synthetic ligands
which they coined pharmacologically selective effectorCurrent Opinion in Neurobiology 2012, 22:54–60
56 Neurotechnologymolecules (PSEMs) [33]. Fusion of these modified
nAChR ligand-binding domains, termed pharmacologi-
cally selective actuator modules (PSAMs), with the ion-
pore domains of different Cys-loop receptors produced
receptor channels with different ion selectivities (cations,
calcium, or chloride). Chimeras of serotonin 5HT3, or
glycine receptor ion-pore domains with PSAMs, showed
potent activation or silencing in brain slices within sec-
onds to minutes after addition of synthetic ligands. Proof
of principle experiments in vivo showed that the chimeric
glycine receptor efficiently suppressed Agouti-related-
protein-expressing (AgRP) neuron-dependent feeding
behavior tens of minutes after intraperitoneal ligand
injection. The exact on/off-kinetics for each designer
receptor will depend on the specific combination of
ligand-binding and ion-pore domains, as well as the
pharmacokinetic properties of the cognate ligand. Many
of these response properties have yet to be determined.
However, a notable advantage of this system is the
potential to use different ligand and receptor channel
combinations to manipulate separate ionic conductances
in different neurons or circuits in the same animal [33].
Allosteric modulation of GABAergic
neurotransmission
While most neuronal manipulation techniques influence
activity irrespective of network state, the ‘zolpidem-
method’ modulates physiological GABAA receptor-
mediated transmission via allosteric pharmacology. Mice
engineered to harbor a point mutation in the ‘floxed’
GABAA receptor g2 subunit show unaltered GABAergic
transmission, but are insensitive to the allosteric ligands
zolpidem and DMCM, which normally enhance and
reduce GABA-induced chloride influx through a1–
3bg2 subunit containing receptors (78% of all GABAA
receptors in mammals), respectively [34–36]. Cell type-
selective reintroduction of the wild-type g2 subunit
together with Cre recombinase allows cell type-selective
subunit swap and reinstatement of drug sensitivity as
shown for cerebellar Purkinje cells [37,38]. In these mice,
zolpidem caused enhanced inhibitory postsynaptic cur-
rents in Purkinje cells in vitro and motor deficits within
minutes after intraperitoneal injection in vivo. The half-
life of zolpidem in rodents is about 20 min [39]. An
advantage of this system is that the same animal may
be used for bidirectional modulation with either zolpidem
or the inverse agonist DMCM. Both drugs can be applied
systemically and can be acutely antagonized with fluma-
zenil [37,38]. A disadvantage is the requirement for a
genetically engineered zolpidem-insensitive background,
which limits its application to mice and rats [40].
Neuronal manipulation using G-protein-
coupled receptors
The brain expresses a large family of G-protein-coupled
receptors (GPCRs), which are activated by a variety of
endogenous and pharmacological ligands. Depending onCurrent Opinion in Neurobiology 2012, 22:54–60 downstream signaling cascades, receptor activation can
have a multitude of cellular effects [41]. These include
the activation, or inactivation of potassium channels,
which in turn lead to reduced or elevated neuronal firing
(Figure 1b). The efficacy of GPCR-mediated neuronal
silencing was nicely shown by transgenic expression of
the Gai-coupled serotonin receptor (Htr1a) in the amyg-
dala of Htr1a/ knockout mice. Treatment with the
selective agonist 8-hydroxy-2-(di-n-propylamino) tetralin
resulted in qualitative changes in conditioned fear
responses [42,43]. A clear caveat of this approach was
the need for a knockout background. Engineered and
heterologously expressed GPCRs address this issue.
Designer GPCRs
As described for engineered ion channels above, one
method to create orthogonal GPCR–ligand pairs is to
render endogenous receptors insensitive to endogenous
ligands, but sensitive to synthetic ones. Systematic
mutations of the k opioid receptor produced receptors
activated solely by synthetic ligands (RASSLs) [44],
which were sensitive only to synthetic agonists. RASSLs
have since been used in vivo to investigate GPCR sig-
naling in different tissues [45–47]. However, baseline
receptor activities and off-target effects of the synthetic
ligands precluded their use for precise brain circuit
manipulation [48,49]. These teething problems were
overcome in a second generation of RASSLs, so called
designer receptors exclusively activated by designer
drugs (DREADDs) [50].
Engineered from muscarinic acetylcholine receptors
(mAChRs), Armbruster and colleagues generated
DREADDs with little or no baseline activity that were
insensitive to endogenous acetylcholine, but potently
activated by the pharmacologically inert molecule cloza-
pine-N-oxide (CNO). Introductions of Y3.33C and A5.46G
mutations generated DREADDs that coupled to Gq, Gi,
(hM1–5D) or Gs (rM3/b1Ds) signaling pathways without
obvious interference with endogenous GPCR signaling
[50,51]. These receptors provided a genetic means for in
vivo cell type-selective activation (Gq-coupled hM3Dq) or
inhibition (Gi-coupled hM4Di) of neuronal activity,
respectively (Figure 1b). Experimentally, pyramidal cells
in hippocampal slices of mice transgenically expressing
HA-tagged hM3Dq in forebrain showed robust phospho-
lipase C-dependent depolarization and increased firing
minutes after CNO application — presumably through
closure of KCNQ channels. Apart from reduced loco-
motion, hM3Dq-expessing mice showed no overt beha-
vioral alterations in the absence of CNO. However,
intraperitoneal injection of CNO caused dose-dependent
and time-dependent increases in hippocampal network
activity and locomotion, with seizures developing at high
doses. Effects developed within 15 min, peaked approxi-
mately one hour post injection, and lasted for 10 hours.
Notably, comparable drug-induced phenotypes werewww.sciencedirect.com
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off-kinetics have been reported for mCherry-tagged
hM3Dq targeted to AgRP neurons of the mouse hypo-
thalamus [53]. In these animals CNO injections
increased feeding behavior within minutes, which lasted
for up to eight hours. Chronic CNO injections caused
weight gain, which reversed after CNO withdrawal [53].
The same authors also expressed the inhibitory
DREADD hM4Di in AgRP neurons, where CNO caused
hyperpolarization and reduced firing in slices (presum-
ably via GIRK channels), as well as reduced food intake
within two hours after intraperitoneal injection [50,53].
In vivo silencing with hM4Di has also been successfully
used to investigate the functions of the striatopallidal or
striatonigral pathways in drug sensitization [54], and the
role of serotonergic neurons in respiratory control and
thermo regulation [55].
Allatostatin receptor
Another method to drive neuronal hyperpolarization and
inhibition of action potential firing has exploited the
Drosophila allatostatin receptor (AlstR). Genetic trans-
plantation of the AlstR into mammalian neurons induces
Gi-coupled GIRK channel-mediated silencing in the
presence of the insect peptide allatostatin (Figure 1b)
[56,57]. In ferret cortical slices, allatostatin efficiently
reduced membrane potential, input resistance, and action
potential frequency within minutes. Similar silencing
responses were reported for AlstR-expressing neurons
in slices of mouse spinal cord, hippocampus, amygdala,
and rat brainstem, as well as cortical neurons in vivo
following surface superfusion with allatostatin [58–62].
In vitro, allatostatin-induced effects could be ‘washed-
out’ within 15 min, but local allatostatin applicationsTable 1
Receptor–ligand systems applied in vivo.
System
(receptor)
Ligand Timescale
induction
Timescale
reversal
B
perm
Activation
TRPV1 Capsaicin d.a. — s d.a. — s Unkn
hM3Dq CNO d.a. — s/min
sys — tens of min
sys — hours Yes 
PSAM-5HT3 PSEMs d.a. — s d.a. — s Yes 
Inhibition
GABAA Zolpidem d.a. — s/min
sys — min
sys — tens of min Yes 
GluCl Ivermectin d.a. — s/min
sys — hours
d.a. — hours
sys — days
Yes 
AlstR Allatostatin d.a. — min d.a. — min/hours No 
hM4Di CNO d.a. — s/min
sys — hours
sys — hours Yes 
PSAM-GlyR PSEMs d.a. — s/min
sys — tens of min
d.a. — s/min Yes 
d.a., direct tissue application in vitro or in vivo; sys, systemic applicati
approximations and may vary with experimental conditions such as route 
www.sciencedirect.com below the brain surface in vivo resulted in neuronal
inactivation for minutes to hours [62]. Whereas Tan
and colleagues found no decrease in silencing efficiency
in the continued or repeated presence of allatostatin,
Wehr et al. reported partial recovery of activity during
allatostatin superfusion, and transient rebounds of hyper-
excitability during washout [60,62]. As allatostatin does
not cross the BBB, it has to be injected locally. Limited
tissue diffusion might account for the reported variability
in silencing efficiency and recovery times [62,63]. Never-
theless, this method has proven successful and has been
widely used in vitro to study single neuron response
properties, and in vivo to delineate the roles of neuronal
subtypes in coordinating locomotor rhythms [61,63],
respiration [58,64], and encoding fear memories [59].
Conclusions
We have entered an era of experimental neurobiology
where imaging, electrophysiological recording, and
genetic manipulation technologies are merging [65].
New methods to manipulate neuronal activity through
optogenetic and chemical genetic methods now allow
interrogation of circuit function from the level of the
synapse to behavior. Although all these methods provide
the power to probe and map neuronal connectivity with
unprecedented resolution, each has its own advantages
and disadvantages. For example, optogenetics provides
temporal control on a millisecond timescale, which in
principle can be used to shape elaborate patterns of
activity to investigate details of neuronal coding [66].
However, optogenetics relies on direct access of photons
to brain tissue, a methodology that requires brain surgery
and is difficult to achieve for prolonged periods of time, or
in distributed neuronal populations. Chemical geneticsBB
eability
Limitations References
own Potential base-line effects, excitotoxicity
with high ligand concentrations
[21–23,25,26]
Slow reversal, cellular effects may very
with signaling pathways
[50,52,53]
Not yet tested in vivo [33]
Requires zolpidem-insensitive background,
no absolute silencing possible
[34–38]
Slow on-/off-kinetics, ligand may be toxic
at higher concentrations
[27–31]
Tissue diffusion of ligand might be limited,
effects depend on signaling pathways
[57–64]
Slow reversal, cellular effects may vary
with signaling pathways
[50,53,54,55]
Requires further characterization in vivo [33]
on in vivo. Note that timescales for induction and reversal are only
of ligand application, target cell-type, and experimental read-out.
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58 Neurotechnologyprovide an alternative and complementary approach to
modulate neuronal activity (see Refs. [53,67] for com-
parison of optogenetics and chemical genetics applied to
the same cell type). However, chemical genetic methods
have their own cast of drawbacks (Table 1). For example,
ivermectin-based inhibition through expression of GluCl
channels relies on the availability of multiple subunits,
and is applicable with timescales of hours to days,
whereas allosteric modulation of GABAergic trans-
mission with zolpidem requires expression of wild-type
g2 subunits plus Cre, and is restricted to mice and rats.
For GPCR-based methods, efficiency and time course of
the manipulation may vary with the availability of down-
stream signaling pathways, and effector molecules in
different cell types and developmental stages. In
addition, G-protein-signaling will have multiple cellular
effects, which may complicate data interpretation in
some experimental settings. Regarding reversibility, it
should be kept in mind that independent of the method a
neuron might not be the same after a manipulation as
before. A great advantage of chemical genetics over
optogenetics is the potential for non-invasive or mini-
mally invasive experimental design through systemic
ligand application. This, however, requires transport of
the ligand across the BBB, which has not yet been
achieved for all systems.
Although neuro-technology is advancing at a breakneck
pace, the challenge remains to further define, build upon,
and optimize the evolving toolset for investigating brain
circuit form and function. New frontiers include the
development of synapse-specific manipulation strategies
as well as the exploration of molecular receivers for
physical signals with easy propagation in brain tissue to
combine advantages of current optogenetic and chemical-
genetic techniques. The functional deconstruction of
neuronal circuits will help to understand human brain
development and disease, and a hope for the future is to
advance some of the creative genetic approaches used in
the lab toward therapeutic design.
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